Using L-selectin shedding to reduce damage after spinal cord injury
L-selectin shedding as a novel therapeutic strategy to mitigate acute secondary damage after spinal cord injury
This study is looking at how a specific immune cell receptor called L-selectin affects inflammation and healing after a spinal cord injury, and it will test if using the medication diclofenac can help improve recovery for people with these injuries.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-10991760 on NIH RePORTER |
What this research studies
This research investigates how L-selectin, a receptor on immune cells, contributes to inflammation and secondary damage following spinal cord injury (SCI). By using diclofenac, an FDA-approved medication, the study aims to promote L-selectin shedding, which may help reduce harmful immune responses and improve recovery outcomes. The research will explore the mechanisms by which L-selectin affects neutrophil activity and tissue damage, with the goal of identifying a new therapeutic approach for SCI patients. If successful, this could lead to better treatment options for those suffering from the effects of spinal cord injuries.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently experienced a spinal cord injury.
Not a fit: Patients with chronic spinal cord injuries or those who do not meet the criteria for acute treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel therapeutic strategy to minimize secondary damage and improve recovery for spinal cord injury patients.
How similar studies have performed: While the approach of targeting L-selectin shedding is relatively novel, previous studies have shown promise in using similar strategies to mitigate inflammation in other contexts.
Where this research is happening
College Station, United States
- Texas A&m University — College Station, United States (Active)
Researchers
- Principal investigator: Mccreedy, Dylan a. — Texas A&m University
- Study coordinator: Mccreedy, Dylan a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.